The best way to predict future is to invent it.
- Alan Kay
28 October 2018:
Syntab Therapeutics has signed an agreement with Efficient Robotics GmbH, Kornwestheim, Germany, in order to create an innovative binder peptide unit capable to synthesize and screen thousands of potential binders within short time. With the help of Efficient Robotics’s microfluidics technology, this unit is up to be realized. A proof-of-principle has already been shown. The co-operation enables Syntab Therapeutics to realize novel immunooncologic drug molecules with strong binding specificities for diverse targets in short time.
14 October 2016:
Syntab Therapeutics is leading the project consortium I3-STM with a total volume of about 3 million Euro. The project is supported by EFRE and the state Northrhine-Westphalia. Next to Syntab, the companies Taros Chemicals, Dortmund, Gremse-IT, Aachen, and TECO Development, Rheinbach, co-operate with 3 academic partners, the Institute of Laboratory Animal Science, the Institute for Experimental Molecular Imaging as well as the Medical Clinic III of the University Hospital Aachen.